Articles tagged with Breast Cancer
Researchers have identified a possible way to reengage a tumor suppressor protein, Growth Differentiation Factor 11, in triple-negative breast cancer cells. This could lead to the development of novel medications that can stop the aggressive form of cancer by intervening in its progression.
A study found that only 20% of Indonesian women are aware of cervical smears, with even lower rates for mammography. Higher education, household expenditure, and health insurance were associated with increased awareness and participation. Experts call for improved education and access to resources to increase cancer screening rates.
A University of Guelph professor has identified a protein called cadherin-22 as crucial in the spread of cancer cells. The discovery could lead to new treatments by hindering the protein's function, reducing adhesion and invasion rates by up to 90%.
A new study found that only a quarter of UK adults understand the connection between weight issues and cancer, despite obesity being linked to 13 types of cancer. The study also highlighted misconceptions about cancer types linked to obesity and the impact of socio-economic background on awareness.
A protein called tyrosine kinase 6 (PTK6) has been identified as a potential therapeutic target for estrogen receptor positive (ER+) breast cancer. PTK6 promotes cancer cell survival and growth in ER+ breast cancer cells, making it a promising avenue for developing new treatments.
A study published in Journal of Cancer Survivorship found that motivation to provide samples for genetic tests depends on oncologist engagement or religion, rather than race. Women with better access to healthcare and a greater sense of well-being were more likely to participate in genetic research.
African American women with type 2 diabetes have a higher risk of developing estrogen receptor negative (ER-) breast cancer, a more aggressive form of the disease. Chronic inflammation from diabetes may contribute to this increased risk, which could help explain the higher incidence of ER- breast cancer in African American women.
African-American women with type 2 diabetes are disproportionately affected by ER-negative breast cancers. The study found a statistically significant association between type 2 diabetes and increased risk of ER-negative breast cancer in black women, particularly those with lower BMI.
A new study published in Gastroenterology found that health insurance coverage differences account for nearly half of the black-white survival disparity in colorectal cancer patients. The study analyzed data from 199,098 CRC patients aged 18-64 and found a significant impact of insurance status on treatment outcomes.
A study published in the Journal of Hepatology found that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of liver, colorectal, and breast cancers. Patients with NAFLD were 16.73 times more likely to develop hepatocellular carcinoma and twice as likely to develop colorectal cancer.
Researchers developed a melanin-enhanced cancer immunotherapy technique using a transdermal patch that promotes the systemic immune response against melanoma. The patch is applied via a skin patch and triggers an immune response, allowing the body's immune system to remember and respond to the presence of melanoma cells.
Researchers developed a targeted approach to immunotherapy by conjugating cancer drugs to peptides that bind to tumor tissues. This method showed promise in mice models, improving efficacy while minimizing treatment-related side effects.
Women with ER-positive breast cancer still face a substantial risk of cancer returning or spreading even 20 years after diagnosis, according to a new analysis. The risk is directly tied to the original cancer's size and characteristics, as well as the number of lymph nodes involved.
Researchers at Rice University and Northwestern University have developed a method to use nanoshells to deliver high doses of cancer-killing drugs inside tumors. The approach uses laser-activated gold nanoparticles to release approved drugs in laboratory cultures, demonstrating clinical applicability.
A study found circulating tumor cells (CTCs) associated with relapse in stage IV melanoma patients, suggesting a potential predictor for high-risk disease progression via liquid biopsy. CTCs were detected in approximately 40% of advanced stage melanoma patients and linked to faster relapse rates.
Zepsyre, a marine-derived anticancer drug, will be commercialized in South Korea under the deal. PharmaMar retains exclusive production rights and will sell to Boryung Pharm for commercial use.
A new study finds that a 70-year-old malaria drug can block immune cells in the liver, allowing nanoparticles to reach cancer cells. The research showed improved drug delivery to breast tumors and accumulation in mouse tumors and lungs.
A new HCI study reveals that a two-drug combination significantly reduces precancerous polyps in FAP patients, leading to near-complete blockade of cancer growth pathways. The treatment also activates immune responses aimed at destroying pre-cancerous polyps.
Researchers observed a significant association between warfarin use and reduced risk of new cancers, particularly prostate, lung, breast, and colon cancers. The findings suggest that warfarin may be protective against certain types of cancer, which could have implications for anticoagulation treatment.
Experts say pre-menopausal women with hormone-dependent advanced breast cancer should be included in clinical trials alongside older women. This could provide valuable insights into the best treatments for these patients, who make up a third of all advanced breast cancer cases globally.
Researchers found that combining targeted drugs with hormone therapy results in a significant increase in the risk of severe or life-threatening adverse events. Most of these side effects are treatable and potentially preventable.
Regular exercise can reduce fatigue and pain, and improve cardiovascular health and quality of life in women with advanced breast cancer. The study found that women who exercised had a 12.3% increase in VO2max compared to the control group, indicating improved oxygen transportation and heart function.
A large survey of breast cancer patients found that nearly one-third went against their doctor's advice and chose not to complete recommended adjuvant anti-cancer therapy. Patients with higher distrust in the healthcare system were more likely to report noncompliance, highlighting the need for strategies beyond boosting physician trust.
Patients with advanced breast cancer who experience delayed disease progression have better quality of life outcomes compared to those whose disease progresses earlier. Delaying progression could be critical in improving health-related quality of life for patients with oestrogen receptor positive, HER2 negative advanced breast cancer.
Researchers found that PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) lacking BRCA mutations. The study suggests that PARP inhibitors may be effective in selected patients with other alterations in DNA damage repair genes.
Researchers mapped genetic alterations in normal mammary duct cells, identifying early changes that precede tumour development. This study provides new insights into breast cancer biology and may lead to more precision in screening and prevention.
A large study of FEA lesions found that only a small percentage (2.4%) upgraded to breast cancer at surgery, while 30% were upgraded to higher-risk but non-cancerous lesions. Surveillance over surgery is recommended for women with FEA who do not have genetic mutations or are not interested in chemoprevention.
The UA Cancer Center research team has discovered that genistein, a compound found in soy foods, can protect BRCA1, a gene crucial in thwarting tumor development in breast tissue. This finding offers new hope for treating triple-negative breast cancers, which currently have no targeted chemotherapy available.
A new open-source machine learning program at Georgia Tech predicts cancer drug effectiveness via genetic data, reducing human bias and increasing accuracy. The program aims to be widely used by researchers to improve treatment outcomes.
The South Carolina Cancer Disparities Research Center aims to understand the reasons behind racial and ethnic health disparities in cancer research. The center will increase SCSU's ability to conduct cutting-edge research, inspire new generations of researchers, and engage the general public in cancer research.
The Cleveland Clinic has developed updated guidelines for accelerated partial-breast irradiation (APBI), a technique that targets radiation to the tumor site only. The new guidelines recommend APBI for a broader range of patients, including younger individuals and those with ductal carcinoma in situ.
A recent study published in the Journal of the National Cancer Institute indicates that pregnancy does not incur a greater risk of relapse for survivors of breast cancer. The study found no significant difference in breast cancer recurrence rates among pregnant and non-pregnant women with a history of ER-positive breast cancer.
A study of women with a 20% or greater lifetime risk of breast cancer found that only 23% underwent MRI screenings, even when the service was available at no cost. Researchers aim to understand why these women are declining screening, which could inform targeted interventions.
A new study published in PLOS ONE demonstrates that Videssa Breast, a liquid biopsy test, can reliably rule out breast cancer in women with dense and non-dense breast tissue. With an over 99% negative predictive value, clinicians can confidently use the test to detect cancer in women with dense breasts.
Researchers argue that identifying molecular subtypes of different cells within tumors can improve breast cancer treatment. They advocate for more accurate diagnostic tests to capture irregularities between tumor cells, which are often treated as a whole.
Rare variants combined with background genetic risk factors may account for many unexplained cases of familial breast cancer. The study identified at least 46 genes that were associated with an increased risk of breast cancer in patients with familial breast cancer.
Research from Helmholtz Zentrum München reveals a new mechanism by which obesity fuels the growth of breast cancer. The enzyme ACC1 plays a central role in this process, and blocking its activity with an antibody treatment can halt this mechanism.
A study published in Lancet Oncology identified MAF amplification as a tool to stratify breast cancer patients for zoledronic acid treatment. In MAF-negative patients, the inclusion of zoledronic acid improved outcomes, while non-postmenopausal MAF-positive patients experienced increased adverse outcomes.
A new study suggests that walking, even at lower-than-recommended levels, is associated with a lower mortality risk compared to inactivity. Regular walking was most strongly linked to reduced risk of respiratory disease and cardiovascular disease mortality.
A study analyzing BRCA testing trends from 2003 to 2014 found a significant spike in testing following the publication of Angelina Jolie's op-ed on gene testing. The test increased 80-fold, with rural areas showing higher follow-up surgical procedure rates compared to urban areas.
For-Robin's monoclonal antibody JAA-F11 successfully targets and kills human breast cancer cells in human tumors grafted into mice, effectively treating triple-negative breast cancer. The company is now focusing on fundraising and preparing for human clinical trials to bring its product from the bench to the bedside.
A machine learning tool can accurately predict which high-risk breast lesions are at low risk of becoming cancerous, allowing for safer monitoring instead of surgery. The model correctly identified 97% of cases and avoided almost one-third of benign surgeries.
A new study found that insurance disparities account for a substantial proportion of the excess risk of death from breast cancer faced by black women. Improving access to care could address much of the existing black/white disparity in breast cancer mortality.
Researchers discovered that high levels of cholesterol metabolism's byproduct 27HC facilitates breast cancer metastasis by hijacking specific immune cells. The study identifies 27HC as a potential drug target to inhibit its creation or actions, offering hope for effective therapies against this aggressive form of cancer.
Researchers from Wellcome Trust Sanger Institute and Royal National Orthopaedic Hospital NHS Trust suggest a clinical trial of PI3K inhibitors for chordoma patients with specific genetic mutations. The study provides promising new treatment options for a rare and aggressive form of bone cancer.
A new study confirms vaginal estrogen is effective in managing sexual and urinary problems of menopause without increasing risk of serious health issues like heart disease and cancer. The WHI data review also clears the use of vaginal estrogen for genitourinary syndrome of menopause.
A clinical trial led by Medical University of South Carolina is investigating frankincense as a possible treatment for breast and colon cancer. The study aims to assess whether boswellic acid, an extract from Indian frankincense, can reduce inflammation and slow tumor growth.
Researchers found that neratinib can block the function of Ras oncogenes through an unexpected process, killing non-small cell lung cancer cells resistant to afatinib. The study also discovered that neratinib triggers a seismic event in the plasma membrane, rapidly reducing expression of mutated K- and N-Ras genes.
Exposure to environmental chemicals, particularly during key windows of susceptibility, increases breast cancer risk. The review highlights the importance of precautionary approaches and stronger chemical safety policies.
A new study reveals that women with breast cancer who received more aggressive treatments were more likely to experience disruptions in employment. Women who underwent bilateral mastectomy with reconstruction had nearly eight times the risk of missing over a month of work compared to those who underwent lumpectomy.
A new study from Michigan Medicine found that women who undergo a bilateral mastectomy with reconstruction are 7.8 times more likely to miss work than those who opt for lumpectomy and radiation therapy.
Research at Sanford Burnham Prebys Medical Discovery Institute suggests that eliminating p62 protein in surrounding stromal tissue can disrupt tumor supply lines. This could lead to new strategies to target non-oncogenic addictions and undermine cancer growth.
A recent study published in Annals of Surgery found that bariatric surgery lowers the risk of developing certain types of cancer, including postmenopausal breast cancer and endometrial cancer, by up to 50% among severely obese patients. The study also showed a significant reduction in risk for colon cancer and pancreatic cancer.
Yale researchers have identified the molecular mechanism driving BRCA1 gene mutations' association with breast cancer, offering hope for personalized treatment plans and increased cancer detection accuracy.
A study found that healthcare professionals' recommendations were the most important factor in driving decisions by women at high risk of breast cancer to take selective estrogen receptor modulators (SERMs) for chemoprevention. The recommendation played a statistically significant role and was associated with attitudes, beliefs, and ex...
A 28-study analysis reveals night shift workers are more likely to develop abdominal obesity and experience an increased risk of obesity compared to permanent day workers. Modifying working schedules to avoid prolonged exposure to long-term night shifts might help reduce this risk, according to the study.
Research led by Dr. Carlos Arteaga has identified potential targets for treating chemotherapy-resistant triple negative breast cancer, including genes MCL1 and MYC. These genes can be targeted with specific drugs to slow or prevent chemotherapy resistance, improving the outlook for this aggressive form of breast cancer.
A new study has found that trastuzumab treatment does not increase the risk of surgical site complications that require intervention after breast reconstruction. Immediate breast reconstruction may be possible for patients receiving trastuzumab alone, but those on combination targeted HER-2 treatment should delay surgery.
US breast cancer death rates are decreasing overall, with a 39% drop since 1989. Black women still face higher mortality rates than white women, but several states have seen significant declines in the gap between the two groups.
The Summer 2017 issue of Family Medicine and Community Health Journal focuses on various topics in family medicine, including prostate-specific antigen testing, health-related quality of life, and breast cancer tumor grade. The journal features six original research articles and one China Focus article.